Vampire bat stroke drug study resumes
Genetically modified protein from vampire bat saliva to treat ischemic stroke.
October 30 2006: 4:07 PM EST
CHICAGO (Reuters) -- An experimental stroke treatment based on the saliva of vampire bats rose from the dead Monday days after a safety panel stalled human testing because of a potential safety risk, its developers said.
An independent panel monitoring clinical trials of the drug said Monday a large study could resume after it halted patient recruitment last week so that it could investigate additional data to evaluate a possible safety issue.
News of the vampire bat drug's revival, which hit a day before the celebration of Halloween, sent shares of the medicine's German developer, Paion AG (Charts), and U.S. partner Forest Laboratories Inc. (up $0.85 to $48.73, Charts) higher.
http://money.cnn.com/2006/10/30/news/co ... tm?cnn=yes